A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aaa0984
Abstract: A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance. Speeding toward CAR T cell therapy for glioblastoma Chimeric antigen receptor (CAR) T cells have been successfully… read more here.
Keywords: glioblastoma; egfrviii; cart egfrviii; car cells ... See more keywords